FDC Share Price Target 2026, 2027, 2030, 2040, 2050
FDC (Fairdeal Corporation) is a well-known Indian pharmaceutical company that makes medicines and healthcare products. The company mainly produces oral rehydration salts (ORS), eye care medicines, and anti-infective drugs. Some of its popular brands include Electral, Zifi, and Enerzal, and Electral is one of the most widely used ORS products in India. It makes both finished medicines and active pharmaceutical ingredients (APIs), which are the main substances used to make medicines, in areas like infections, stomach problems, vitamins, and skin care.
What is FDC Ltd NSE: FDC?
FDC was established in 1936 in Mumbai, India, founded by Anand Chandavarkar. It is an Indian healthcare and pharmaceutical company that makes and sells many types of medicines and health products such as tablets, capsules, eye drops, vitamin supplements, and electrolyte drinks. The company is well known for popular products like Electral ORS, Enerzal, Zifi, and Zocon. FDC also makes active pharmaceutical ingredients (APIs), which are the main substances used to produce medicines. Its products are sold across India and exported to more than 50 countries.
It is a well-known pharmaceutical and healthcare company from India that has been working in the medical field for many years. Over time, it has become known for making good-quality and affordable healthcare products. It develops, makes, and sells many types of medicines and health products that are used by doctors, hospitals, and patients. The company works in different healthcare areas and focuses on improving people’s health by providing safe and effective medicines. In 2026, its share price target would be ₹555, as per stock market analysts.
According to stock market analysts, its share price would be between ₹298 to ₹555 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 298 | 555 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 358 | 422 |
| February | 350 | 400 |
| March | 312 | 404 |
| April | 298 | 414 |
| May | 312 | 421 |
| June | 344 | 442 |
| July | 363 | 479 |
| August | 374 | 490 |
| September | 390 | 511 |
| October | 435 | 522 |
| November | 445 | 538 |
| December | 465 | 555 |
It has a clear goal of improving people’s health by providing good-quality medicines and healthcare products. Its mission is to research, develop, produce, and supply medicines that meet high-quality standards while still being affordable for patients. It also works to build strong and long-term relationships with doctors, hospitals, and healthcare providers by keeping trust in its products. The company believes in new ideas, responsibility, and customer satisfaction. In 2027, its share price target would be ₹734, as per stock market analysts.
According to stock market analysts, its share price would be between ₹539 to ₹734 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 539 | 734 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 539 | 587 |
| February | 547 | 600 |
| March | 558 | 621 |
| April | 560 | 633 |
| May | 566 | 648 |
| June | 569 | 655 |
| July | 600 | 667 |
| August | 607 | 675 |
| September | 611 | 681 |
| October | 618 | 689 |
| November | 625 | 711 |
| December | 642 | 734 |
It makes many different types of medicines and healthcare products used to treat various health problems. These include tablets, capsules, syrups, powders, creams, and eye drops. The company also produces electrolyte solutions, nutritional supplements, and vitamins that help people recover from illness and stay healthy. Many of these medicines are commonly prescribed by doctors in hospitals and clinics across India. It carefully develops its products to make sure they are safe, effective, and easy for patients to use. In 2028, its share price target would be ₹918, as per stock market analysts.
According to stock market analysts, its share price would be between ₹720 to ₹918 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 720 | 918 |
It works in many medical areas, which means its medicines are used to treat different types of diseases and health problems. The company provides medicines for infections, stomach problems, eye diseases, skin problems, heart-related conditions, and breathing issues. It also makes vitamin supplements and nutrition products that help support overall health. Because it works in many healthcare segments, it can serve many different patients with different needs. This wide range of medicines helps the company stay competitive in the pharmaceutical industry. In 2029, its share price target would be ₹1095, as per stock market analysts.
According to stock market analysts, its share price would be between ₹889 to ₹1095 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 889 | 1095 |
The company has built a strong manufacturing network with several production plants across India. These factories are located in places such as Goa, Baddi, Roha, Waluj, and Sinnar. Each plant uses modern machines and follows strict quality checks to make sure medicines are produced safely and correctly. The company produces both finished medicines and active pharmaceutical ingredients, which are the main substances used to make medicines. In 2030, its share price target would be ₹1332, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1075 to ₹1332 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 1075 | 1332 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1075 | 1168 |
| February | 1090 | 1185 |
| March | 1102 | 1200 |
| April | 1117 | 1220 |
| May | 1128 | 1235 |
| June | 1138 | 1244 |
| July | 1150 | 1259 |
| August | 1167 | 1266 |
| September | 1185 | 1282 |
| October | 1199 | 1290 |
| November | 1211 | 1315 |
| December | 1250 | 1332 |
The company also has research centres where scientists and medical experts work to develop new medicines and improve existing ones. These research teams study different health problems and try to create better treatments that can help patients recover faster. They also work on improving how medicines are made and used so that they are easier to take and more effective. The company tries to bring better healthcare products in the future while maintaining high quality and safety standards. In 2040, its share price target would be ₹2300, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2006 to ₹2300 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 2006 | 2300 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2006 | 2088 |
| February | 2011 | 2125 |
| March | 2028 | 2139 |
| April | 2032 | 2155 |
| May | 2048 | 2175 |
| June | 2055 | 2189 |
| July | 2068 | 2200 |
| August | 2084 | 2221 |
| September | 2100 | 2238 |
| October | 2122 | 2252 |
| November | 2141 | 2274 |
| December | 2189 | 2300 |
This company also sells its medicines in many countries around the world. The company exports its products to more than 50 countries across regions such as Asia, Africa, and Europe. Through partnerships with distributors and healthcare organisations, it makes sure its medicines reach hospitals, pharmacies, and patients in other countries. This global presence has helped the company grow its business and build a strong reputation in the pharmaceutical industry. In 2050, its share price target would be ₹3440, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3124 to ₹3440 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 3124 | 3440 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 3124 | 3233 |
| February | 3142 | 3254 |
| March | 3158 | 3266 |
| April | 3174 | 3282 |
| May | 3200 | 3290 |
| June | 3221 | 3305 |
| July | 3237 | 3318 |
| August | 3248 | 3335 |
| September | 3255 | 3354 |
| October | 3269 | 3378 |
| November | 3284 | 3390 |
| December | 3321 | 3440 |
Should I buy FDC stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 298 | 555 |
| 2027 | 539 | 734 |
| 2028 | 720 | 918 |
| 2029 | 889 | 1095 |
| 2030 | 1075 | 1332 |
| 2040 | 2006 | 2300 |
| 2050 | 3124 | 3440 |
The company sells well-known healthcare products and also exports medicines to many countries, which helps it earn steady revenue. However, the company’s profit growth has been slower in recent years, and the stock price is very low compared to some other pharma companies. Because of this, the stock could be better for investors who want a stable company for long-term investment rather than very fast growth.
FDC earnings results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
| Sales + | 1,341 | 1,331 | 1,525 | 1,784 | 1,943 | 2,108 | 2,078 |
| Expenses + | 1,038 | 997 | 1,271 | 1,533 | 1,604 | 1,783 | 1,798 |
| Operating Profit | 304 | 334 | 254 | 251 | 339 | 325 | 280 |
| OPM % | 23% | 25% | 17% | 14% | 17% | 15% | 13% |
| Other Income + | 57 | 95 | 76 | 50 | 102 | 91 | 72 |
| Interest | 3 | 3 | 3 | 4 | 4 | 5 | 5 |
| Depreciation | 37 | 38 | 37 | 39 | 40 | 54 | 60 |
| Profit before tax | 320 | 388 | 289 | 258 | 396 | 357 | 288 |
| Tax % | 25% | 22% | 25% | 25% | 23% | 25% | |
| Net Profit + | 240 | 301 | 216 | 194 | 305 | 267 | 217 |
| EPS in Rs | 14.03 | 17.85 | 12.82 | 11.70 | 18.75 | 16.39 | 13.31 |
| Dividend Payout % | 6% | 0% | 0% | 0% | 0% | 31% |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 27.91 | 2.65 | 1.35% | 36.22 | 5.72 | 0.59% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| F D C Ltd | 22.67 | 2.65 | 1.35% |
| Sun Pharmaceutical Industries Ltd | 38.43 | 5.79 | 0.91% |
| Torrent Pharmaceuticals Ltd | 76.87 | 19.36 | 0.74% |
| Dr Reddy’s Laboratories Ltd | 19.01 | 3.17 | 0.62% |
Is FDC stock good to buy? (bull case & bear case)
Bull Case:
- It has a market value of about ₹5,999 crore, which shows it is a mid-sized pharmaceutical company with a stable position in the healthcare industry.
- The company is almost debt-free, which means it has very little debt and its financial condition is quite safe.
- It has a Return on Capital Employed (ROCE) of about 16.4%, which means the company is using its business money in a fairly good way to earn profit.
- The company has a Return on Equity (ROE) of around 12.1%, which shows it gives moderate returns to its shareholders.
- The company’s profit growth in the last 5 years is around 12–13%, which shows stable improvement in earnings.
Bear Case:
- The company’s sales growth has been around 9% in the last five years, which is a bit slow compared to some fast-growing pharma companies.
- The ROE of about 11–12% is not very high, which means the company is not generating very strong returns from shareholders’ money.
- The pharmaceutical industry has high competition, especially in generic medicines, which can sometimes reduce the company’s profit margins.
Conclusion
It is a well-known Indian pharmaceutical company that has been working in the healthcare industry for many years. The company has popular products like Electral, Zifi, and Enerzal, which are widely used in India. It sells its medicines across the country and also exports them to more than 50 countries, which helps the company earn stable revenue. Its financial performance shows steady growth in sales and profits, and the company has very little debt, which makes its financial position strong and safe. If the company continues to grow its products, improve research, and expand into global markets, it may see steady growth in the future.
